Document:

exv10w15

 

Exhibit 10.15

	 	 	 	 	 

Applera

301 Merritt 7

Norwalk, CT 06851

MetaMorphix, Inc.

8510 A Corridor Road

Savage Road, MD 20763

Attn: Edwin Quattlebaum, Chairman and CEO

	 	Re:   	 Livestock Database License Agreement effective as of February 28, 2002
by and between Applera Corporation, a Delaware corporation (successor to its
wholly-owned subsidiary PE CORPORATION (NY), a New York corporation), through
the Celera Genomics Group (“Celera”), and MetaMorphix, Inc., as amended (the
“License Agreement”).

Ladies and Gentlemen:

     This letter will serve as confirmation of the agreement by Applera Corporation, acting through
Celera and MeteMorphix, Inc. to emend the License Agreement to extend certain option and payment
deadlines as follows:

     Sections 2.4 and 4.1(b) of the License Agreement are hereby amended as follows:

     1. All references to September 1, 2003 in such sections are changed to September 9, 2003

     This Amendment No. 2 shall be deemed to be an amendment to the License Agreement.
All references to the License Agreement in any other document, instrument agreement or writing
hereafter shall be deemed to refer to the License Agreement as amended hereby. However, except
as expressly provided herein, the License Agreement shall remain in full force and effect
without amendment or modification. This Amendment contains the entire agreement and
understanding of the parties regarding the subject matter of this Amendment

	 	 	 	 	 
	 	Very truly yours,

APPLERA CORPORATION, acting through

its Celera Genomics Group 

 	 
	 	By:  	
/s/ Thomas P. Livingston
 	 
	 	 	Name:  	Thomas P. Livingston 	 
	 	 	Title:  	Secretary 	 
	 

Agreed and Accepted as of the date first above written

	 	 	 	 	 
	 	METAMORPHIX, INC.

 	 
	 	By:  	/s/ Michael R.N. Thomas
 	 
	 	 	Michael R.N. Thomas, CFO and Treasurerexv10w16

 

Exhibit 10.16

	 	 	 	 	 

September 8, 2003

MetaMorphix, Inc.

8510 A Corridor Road

Savage, MD 20763

Attn: Edwin Quattlebaum, Chairman and CEO

	 	Re:   	 Livestock Database License Agreement effective as of February 28, 2002 by
and between Applera Corporation, a Delaware corporation (successor to its
wholly-owned subsidiary PE CORPORATION (NY), a Now York corporation), through the
Celera Genomics Group (“Celera”), and MetaMorphix, Inc., as previously amended
(the “License Agreement”)

Ladies and Gentlemen:

     This letter will serve as confirmation of the agreement by Applera Corporation, acting
through Celera, and MetaMorphix, Inc. to amend the License Agreement to extend certain option
and payment deadlines as follows:

          Sections 2.4 and 4.1(b) of the license Agreement are hereby amended as follows:

     1. All references to September 9, 2003 in such sections are changed to October 1 2003.

     This Amendment No. 3 shall be deemed to be an amendment to the License Agreement. All
references to the License Agreement in any other document, instrument, agreement or writing
hereafter shall be deemed to refer to the License Agreement as amended hereby. However, except
as expressly provided herein, the License Agreement shall remain in full force and effect
without amendment or modification. This Amendment contains the entire agreement and
understanding of the parties regarding the subject matter of this Amendment.

	 	 	 	 	 
	 	Very truly yours,

APPLERA CORPORATION, acting through its 

Celera Genomics Group 

 	 
	 	By /s/ Ugo DeBlasi
 	 
	 	Name:  	Ugo DeBlasi 	 
	 	Title:  	VP and Corporate Controller 	 
	 

Agreed and Accepted as of the date first above written

	 	 	 	 	 
	 	METAMORPHIX, INC.

 	 
	 	By:  	/s/ Michael R.N. Thomas
 	 
	 	 	Michael R.N. Thomas, CFO and Treasurerexv10w17

 

Exhibit 10.17

	 	 	 	 	 

As of October 1, 2003

MetaMorphix, Inc.

8510 A Corridor Road

Savage Road, MD 20763

Attn: Edwin Quattlebaum, Chairman and CEO

	 	   	Re: Amendment No. 4 to the Livestock Database License Agreement effective as of
February 28, 2002, as amended to date (the “License Agreement”) and Amendment No. 2 to
the Subscription Agreement effective            as            of February 28, 2003, as amended to
date (the “Subscription Agreement"), each by and between Applera
Corporation, a Delaware corporation (successor to its wholly-owned subsidiary PE
CORPORATION (NY), a New York corporation), through the Celera Genomics Group
(“Celera”), and MetaMorphix, Inc., a Delaware corporation (the
"Company"); and Agreement regarding the Company’s Certificate of
Designations for its Series E Convertible Preferred Stock (the
“Certificate”)

Ladies and Gentlemen:

This letter (the “Amendment and Agreement”) will serve as confirmation of the agreement by
Applera Corporation, acting through Celera, and the Company to the following:

	 	(a)  	Applera Corporation and the Company agree to amend the License Agreement
(most previously amended by letter agreement dated September 8, 2003) and the
Subscription Agreement (as amended by agreement dated June 17, 2003) to extend
certain option and payment deadlines as follows:

	 	1)  	Sections 2.4 and 4.1(b) of the License Agreement are hereby
amended by changing all references therein to October 1, 2003 to December
12, 2003.
	 
	 	2)  	Sections 2.4, 4.1(b) and 4.1(c) of the License Agreement are
hereby amended by changing all references to June 1, 2003 to October 1, 2003.
	 
	 	3)  	Paragraph II of Exhibit 3 to the Subscription Agreement is
hereby amended by changing all references to June 1, 2003 to October 1, 2003.

     (b) The Company agrees that if, in connection any Company financing or other transactions
or events occurring on or after the date hereof, Applera Corporation’s anti-dilution rights
would be triggered under Section 6(e) of the Certificate (the “Anti-Dilution Provision”), then
at the request of Applera Corporation, in its sole discretion based on considerations that it
deems commercially necessary, appropriate, or advisable, the Company shall cooperate with

 

 

Applera Corporation and negotiate with Applera Corporation in good faith (either before or
after the financing or other transaction or event, depending on the timing of the request) to
modify or alter the mechanics of the Anti-Dilution Provision or enter into alternative
arrangements having a substantially equivalent purpose and effect; in either case on terms
acceptable to Applera Corporation in its sole discretion provided, that in no event shall the
Company’s obligations under this paragraph require it to amend the Certificate or enter into other
arrangements that would result, directly or indirectly, in Applera Corporation receiving
beneficial ownership of equity in the Company to a greater extent than is provided in the
Certificate, and in particular the Anti-Dilution Provision, as in effect from time to time.

     This Amendment and Agreement shall be deemed to be an amendment to the License Agreement and
the Subscription Agreement. All references to the License Agreement or the Subscription Agreement
in any other document, instrument, agreement or writing hereafter shall be deemed to refer to the
License Agreement or the Subscription Agreement, as the case may be, as amended hereby. However,
except as expressly provided herein, the License Agreement and the Subscription Agreement shall
remain in full force and effect without amendment or modification. This Amendment and Agreement
does not constitute an amendment to the Certificate in any respect. This Amendment and Agreement
shall become effective execution and delivery by
both parties as indicated below, and upon such effectiveness it shall be deemed to contain the
entire agreement and understanding of the parties regarding its subject matter.

	 	 	 	 	 
	 	Very truly yours,

APPLERA CORPORATION, acting through

its Celera Genomics Group

 	 
	 	By:  	/s/
Ugo DeBlasi	 
	 	 	Name:  Ugo DeBlasi	 
	 	 	 	 
	 

Agreed and Accepted as of the date first above written

	 	 	 	 	 
	METAMORPHIX, INC. 
	 
	By:  	/s/ Michael R. N. Thomas
 	 
	 	 	Michael R. N. Thomas, CFO and Treasurer 	 
	 	 	 	 

2exv10w18

 

	 	 	 	 	 

Exhibit 10.18

8510A Corridor Road

Savage. Maryland 2076

Telephone 301 617-9080

Facsimile 301 617-9075

May 28, 2004

Applera Corporation, acting by and through its Celera Genomics Group

PE Corporation (NY)

301 Merritt 7

Norwalk, Connecticut 06851-1070

	 	   	Re: Amendment No. 5 to livestock Database License Agreement effective as
of February 28, 2002, as amended to date through the October 1, 2003 Amendment
No. 4 (the “License Agreement”), by and between Applera Corporation, a
Delaware Corporation (successor to its wholly-owned subsidiary, PE CORPORATION
(NY), a New York corporation), through the Celera Genomics Group (“Celera”),
and MetaMorphix, Inc., a Delaware corporation (“MMI”)

Ladies and Gentlemen:

     This Amendment No. 5 shall serve as confirmation of the agreement by Applera
Corporation, acting through its Celera Genomics Group, to amend the License Agreement
(most previously amended by the letter agreement dated October 1, 2003) as follows:

	1.  	MMI anticipates entering into a “Swine Improvement Agreement” with Monsanto, which
would be a “Porcine Deal” and result in Monsanto being MMI’s “Foundation Customer”
for the “Porcine Product” (as these terms are defined in the License Agreement).

	2.  	As part of the Swine Improvement Agreement, MMI anticipates providing Monsanto with
a license to access any and all swine genomics information owned, licensed by, or
otherwise controlled by MMI, (including without limitation porcine sequence reads
and consensus sequence, identification of the animal/breed from which each sequence
was derived, sequence contig files identifying the approximately 631,000 “in silico”
single nucleotide polymorphisms (SNPs), and comparative sequence analysis from which
approximately 217,000 porcine SNPs with synteny to human sequences were identified)
(the “Anticipated Porcine License(s)”). Notwithstanding anything in Sections 2.1,
2.2, 2.6(b), and any other Section of the License Agreement that would be deemed to
prevent MMI from accomplishing the Anticipated Porcine License(s), and contingent at
all times upon the obligations of Section 3 of this Amendment No. 5, Celera does
hereby consent to allow MMI to sublicense to Monsanto Company, its successors and
assigns (“Monsanto”), and thereby provide access to Monsanto of the porcine-specific
portions (or other portions deemed relevant or necessary to Monsanto’s use of the
Anticipated Porcine License(s)) of the “Agreement Products and Technology,” “EPP
Subscription;" and “EPP SNP Map Subscription” (as these terms are defined
in the License Agreement). Notwithstanding anything in this Amendment No. 5 to the
contrary, the Anticipated Porcine License (s) shall provide in all relevant parts
that Monsanto may not

 

 

Applera Corporation, acting by and

through its Celera genomics Group

May 23, 2004

Page 2

sublicense such “Agreement Products and Technology,” “BPP Subscription,” and “BPP SNP
Map Subscription”, including any of the contents thereof, to Monsanto’s sublicensees and
shall not permit access to such information to Monsanto’s sublicensees.

	3.  	Celera’s consent extended to MMI under Section 2 of this Amendment No. 5 may be immediately
revoked and rescinded by Cetera upon any of the following events:

	 	i.  	MMI’s failure to execute with Monsanto the Swine Improvement Agreement by
June 30, 2004;
	 
	 	ii.  	Monsanto’s failure to make payment to MMI as specified in the Swine
Improvement Agreement; or
	 
	 	iii.  	MMI’s failure to make payment to Cetera as specified in this Section 3 below.

Notwithstanding anything in Section 6.3 of the License Agreement to the contrary, MMI shall
pay the $1,000,000 due to Celera upon receiving consideration for a Porcine Deal, in two
installments, as follows: the first $500,000 payment to be received by MMI from Monsanto
(which is due within thirty (30) days after signing the Swine Improvement Agreement) shall
be paid to Celera by wire transfer within twenty-four (24) hours of MMI’s receipt of it and
the second $500,000 payment (which is due to MMI thirty (30) days after its delivery of the
MMI Swine Genomics Database) shall be paid to Celera by wire transfer within twenty-four
(24) hours of MMI’s receipt of it. MMI shall notify Celera immediately in the event that
Monsanto fails to make payment to MMI as required by the Swine Improvement Agreement.

[The Remainder of this Page is intentionally left blank]

 

 

Applera Corporation, acting by and

through its Celera genomics Group

May 28, 2004

Page 3

     This Amendment No. 5 shall be deemed an amendment to the License Agreement. All
references to the License Agreement and any document, instrument, agreement, or writing
hereafter shall be deemed to refer to the License Agreement, as amended by this Amendment
No. 5 (and the prior four Amendments). However, except as expressly provided herein, the
License Agreement shall remain in full force and effect without amendment or modification.
This Amendment shall be effective as of May 28, 2004, upon (and not before) its execution
and delivery by both parties as indicated below and, upon such effectiveness, it shall be
deemed to contain the entire agreement and understanding of the parties regarding its
subject matter.

	 	 	 	 	 
	 	Very truly yours,

METAMORPHIX, INC.

 	 
	 	By:  	/s/ Edwin . Quattlebaum
 	 
	 	 	Edwin . Quattlebaum Ph.D. 	 
	 	 	President and CEO 	 
	 

Accepted and Agreed as of May 28, 2004 by:

APPLERA CORPORATION, acting through Its
Celera Genomics Group

	 	 	 	 	 
	 	 	 
	 	By:  	/s/ Ugo DeBlasi
 	 	 
	 	 	Name:  	Ugo DeBlasi 	 
	 	 	Title:  	Vice President and Controller

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]